WILLIAM G WIERDA to Clinical Trials as Topic
This is a "connection" page, showing publications WILLIAM G WIERDA has written about Clinical Trials as Topic.
Connection Strength
0.584
-
International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. Blood. 2020 05 21; 135(21):1859-1869.
Score: 0.085
-
Does FCR have the potential to cure a subgroup of patients with chronic lymphocytic leukemia? Clin Adv Hematol Oncol. 2019 Apr; 17(4):214-216.
Score: 0.079
-
NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019. J Natl Compr Canc Netw. 2019 Jan; 17(1):12-20.
Score: 0.077
-
The use of obinutuzumab in chronic lymphocytic leukemia. Clin Adv Hematol Oncol. 2014 Jun; 12(6):395-7.
Score: 0.056
-
Richter's transformation in chronic lymphocytic leukemia. Curr Hematol Malig Rep. 2007 Oct; 2(4):265-71.
Score: 0.035
-
Gene therapy and active immune therapy of hematologic malignancies. Best Pract Res Clin Haematol. 2007 Sep; 20(3):557-68.
Score: 0.035
-
Initial therapy for patients with chronic lymphocytic leukemia. Semin Oncol. 2006 Apr; 33(2):202-9.
Score: 0.032
-
Current and investigational therapies for patients with CLL. Hematology Am Soc Hematol Educ Program. 2006; 285-94.
Score: 0.031
-
Novel immune-based treatment strategies for chronic lymphocytic leukemia. J Clin Oncol. 2005 Sep 10; 23(26):6325-32.
Score: 0.031
-
Evolution of treatment strategies in chronic lymphocytic leukemia. Part 2 of a 3-Part series: Advances in the treatment of hematologic malignancies. Clin Adv Hematol Oncol. 2005 Aug; 3(8):1-10; quiz 11-2.
Score: 0.030
-
Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship. Cancer. 2017 02 15; 123(4):609-616.
Score: 0.017
-
Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials. Lancet Haematol. 2015 Mar; 2(3):e118-28.
Score: 0.015
-
Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood. 2015 Mar 26; 125(13):2062-7.
Score: 0.015
-
CARs in chronic lymphocytic leukemia -- ready to drive. Curr Hematol Malig Rep. 2013 Mar; 8(1):60-70.
Score: 0.013
-
Therapy-related myeloid neoplasms following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Mod Pathol. 2012 Feb; 25(2):237-45.
Score: 0.012
-
Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia. Cancer. 2011 Sep 01; 117(17):3999-4008.
Score: 0.011
-
Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase. Cancer. 2009 Aug 15; 115(16):3709-18.
Score: 0.010